Glaucoma by Williams, SEI
Glaucoma, a major cause of worldwide irreversible blindness, is 
a progressive optic neuropathy that is characterised by specific 
structural changes to the optic nerve head and associated functional 
(visual field) changes. This particular neuropathy involves apoptosis 
of the retinal ganglion cells whose axons comprise the optic nerve. 
The pathogenesis of this apoptosis is poorly understood, but it 
is thought to be a cascade set in motion by mechanical factors 
(elevated intraocular pressure (IOP)) or vascular factors or a 
combination of these two factors (Fig. 1).
Diagnosis of glaucoma
The diagnosis of glaucoma is made when both the functional and 
the structural changes that are the consequence of this apoptosis 
can be demonstrated.
Structural changes in glaucoma
In cross-section the optic nerve head (optic disc) has a central 
depression where the retinal vessels enter the eye. This is known as 
the ‘cup’ (Fig. 2). As peripheral nerve fibres are lost in glaucoma, so 
the remaining fibres take their places, leaving a larger ‘cup’ (Fig. 3).
With progressive axonal loss there is progressive ‘cupping’ of the 
optic nerve head, the end result of which is the fully cupped disc 
– the disc with cavernous optic atrophy (Fig. 4).
Cupping of the optic disc may be appreciated on fundoscopy as an 
area of central pallor. The degree of cupping is measured as a ratio 
of the cup size to the disc size (Fig. 5).
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Fig. 1. The pathogenesis of apoptosis in glaucoma.
Fig. 3. Moderate cupping of the 
optic disc.
Fig. 4. Cavernous optic atrophy 
– fully cupped disc.
Fig. 2. Normal optic disc with a schematic cross-section demonstrating 
the central cup.
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Because some degree of cupping is 
normal and because some people have 
physiologically enlarged cups, the following 
general guidelines apply. Cupping is 
suspicious if:
•   the cup/disc ratio is greater than 0.5
•    the vertical cup/disc ratio is greater than 
the horizontal cup/disc ratio
•    there is asymmetry between the cup/disc 
ratios of the two eyes of more than 0.2.
While it is possible to assess cupping 
subjectively on fundoscopy, it is preferable 
to have an objective assessment that allows 
proper evaluation of progression. 
Objective assessments can be made 
with colour photography, stereoscopic 
photography, optical coherence tomography 
(OCT – high-resolution, cross-sectional 
imaging of the retina using optical technology 
analogous to ultrasonography) (Fig. 6), and 
confocal scanning laser ophthalmoscopy 
(Heidelberg Retina Tomograph or HRT).1 
These last two special investigations can also 
evaluate the thickness of the retinal nerve 
fibre layer (RNFL) surrounding the optic 
disc. The thinning of the peripapillary RNFL 
is a sensitive indicator of glaucomatous 
axonal loss. This can also be assessed using 
scanning laser polarimetry (Nerve Fiber 
Analyser or GDx VCC) (Fig. 7). 
The diagnosis of glaucoma cannot be made 
on the basis of structural changes alone. 
The diagnosis rests on demonstrating the 
structural change in combination with a 
congruous functional change.
Functional changes in glaucoma
The axonal loss that is the hallmark 
of glaucoma begins with axons in the 
periphery of the nerve. These axons have 
their origins in the retinal ganglion cells in 
the retinal mid-periphery with consequent 
visual field fallout in these regions. These 
‘scotomas’ that develop in the visual field 
often go unnoticed by the patient. Formal 
automated perimetry (visual field testing) 
is the best way of detecting these defects. In 
this type of testing the patient is presented 
with targets of differing intensity at different 
points within their visual field. The end 
result is a printout of their visual threshold 
at these different points (Fig. 8). A quick way 
of assessing the visual field is to look at the 
grey-scale representation of the field (Fig. 
9). The normal visual field is described as a 
‘hill’ of vision with the best acuity at fixation 
tailing out to the periphery. The ‘blind spot’ 
corresponds to the optic nerve head and is 
at about 15 degrees temporal to the point of 
fixation.
In glaucoma there is initially an enlargement 
of the blind spot followed by mid-peripheral 
‘arcuate’ scotomas (Fig. 10). These cross the 
vertical midline (distinguishing them from 
neurological deficits) and may be in the 
superior or inferior hemispheres or both. In 
end-stage glaucoma the patients have tunnel 
vision when all but the central area of fixation 
is involved (Fig. 11). At this advanced stage, 
despite the enormous visual field fallout, the 
patient may still have a normal visual acuity 
as tested on a Snellen chart! 
This type of testing has limitations:
•   it is subjective
•   it requires concentration and is tiring
•   it does not detect early damage.
For these reasons the following tests have 
been developed:
Fig. 5. A disc with a cup: disc ratio of 0.5.
Fig. 6. OCT of the optic nerve head showing the cup.
Fig. 7. Gdx showing thinning of the RNFL in the right eye.
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•    short wavelength automated perimetry 
(SWAP) which uses a blue on yellow 
stimulus to pick up early defects1
•    frequency doubling technology (FDT) 
which is a shorter test and uses a flickering 
sinusoidal grating as a target, and may 
detect earlier damage1
•    multifocal visual evoked potentials 
(mVEP) use multiple recording channels 
to detect signals from all areas of the 
visual field to provide an objective map of 
visual function.2
The field losses are significant if they occur 
in the context of a cupped disc and if the 
degree of visual field defect corresponds with 
the degree of cupping. Both structural and 
functional tests are invaluable in following 
patients with established glaucoma to assess 
progression, the rate of progression and/or 
the response to treatment.
Intraocular pressure
So where does intraocular pressure (IOP) 
fit in? IOP takes no part in the diagnosis of 
glaucoma. In fact one may have glaucoma 
in the absence of a raised pressure (normal 
tension glaucoma) and a raised pressure 
without glaucoma (ocular hypertension). 
IOP is, however, still very important in 
glaucoma because it is the most important 
risk factor for glaucoma. In addition, 
lowering the IOP is currently the only way 
we have to treat glaucoma.
Determinants of IOP  (Fig. 12)
IOP is determined by the dynamics of 
aqueous humour production and outflow. 
Aqueous humour is produced by the ciliary 
body and flows over the lens into the 
anterior chamber of the eye. The trabecular 
meshwork lies circumferentially in the angle 
of the eye and 90% of aqueous exits the eye 
via this fine network of fibres into the canal 
of Schlemm, which connects to the episcleral 
venous circulation via aqueous veins. The 
remaining aqueous leaves the eye directly 
via uveoscleral outflow. Aqueous production 
is usually constant, so a raised IOP is usually 
the result of increased resistance to outflow 
at the level of the trabecular meshwork.
Measuring IOP
The Goldmann tonometer (a slit-lamp 
mounted tonometer) is the gold standard 
for IOP measurement. It uses the principle 
of Fick’s Law (IOP equals the force divided 
by the area of application of that force) 
assuming that the eye is a perfect sphere. 
The air-puff tonometer used by optometrists 
works on a similar principle.
A normal IOP (based on population studies) 
is one between 8 and 21mmHg.
Treatment of glaucoma
In theory there are a number of potential 
ways to treat glaucoma:
•    Neuroprotection. This is the ideal 
treatment for a neuropathy and thus there 
is active research into neuroprotective 
agents for the treatment of glaucoma.3 
A prospective, placebo-controlled, 
multi-institutional trial of memantine 
(an NMDA antagonist) in glaucoma is 
currently underway.
•    Increasing ocular blood flow. There is 
strong evidence that ocular blood flow 
alterations are present in patients with 
glaucoma, but there is no gold-standard 
method for its measurement.4 This makes 
it difficult to prove that any agent can 
successfully increase the blood flow. This 
is still an area of active research.
•    Decreasing the IOP. In practice this is 
the only way we currently have to treat 
glaucoma. This may be accomplished 
medically, with the use of lasers or 
surgically. 
Principles of glaucoma treatment
Glaucoma treatment is individualised. The 
first step is to set a target IOP based on the 
patient’s age, the presenting IOP and how 
advanced the disease is. In general the IOP 
should be decreased by about 30% and 
should be below 18 mmHg at all times. The 
more advanced the disease, the lower the 
target IOP should be. Once therapy has been 
instituted the patient needs to be followed 
for progression. If there is progression, 
the target IOP needs to be lower. Usually a 
stepwise approach is used, beginning with 
medical therapy and progressing to surgical  
treatment only when this fails. 
Medical therapy (Fig. 13)
Acetazolamide is the only systemic 
treatment available for glaucoma. It is very 
useful in acute settings and may be used 
intravenously, intramuscularly and orally. 
The disadvantage is the numerous systemic 
side-effects the most common of which 
are malaise, gastrointestinal symptoms and 
paraesthesias.
The topical agents may be used alone or 
in combination to achieve maximum IOP 
lowering. Several fixed combination agents 
are available which improve compliance in 
patients on dual or triple therapy. Most of 
the agents have few systemic side-effects. 
Fig. 8. A normal field on automated perimetry.
Fig. 9. Grey scale view of a normal field.
Fig. 10. A superior arcuate scotoma.
Fig. 11. Tunnel vision.
Fig. 12. The drainage angle of the eye 
demonstrating aqueous humour dynamics.
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The group of beta blockers is a notable 
exception. Despite being topical agents these 
are well absorbed by the nasal mucosa and 
have the same side-effect profile as their oral 
counterparts. They are very effective anti-
glaucoma agents and are commonly used, 
so the cardiac and pulmonary complications 
occur with regularity.
Laser therapy
Aqueous outflow may be enhanced by 
modifying the trabecular meshwork in laser 
trabeculoplasty.
Aqueous production is diminished by 
damaging the ciliary processes in diode 
laser cyclophotocoagulation for refractory 
glaucoma.5
Glaucoma surgery 
The rationale for glaucoma surgical 
procedures is to bypass the trabecular 
meshwork.
In a trabeculectomy (the most widely 
performed incisional glaucoma surgery 
worldwide5) a partial thickness flap is 
formed in the sclera (Fig. 14). Deep to this 
flap a sclerostomy is cut into the anterior 
chamber. A peripheral iridectomy completes 
an uninterrupted fistula for aqueous to pass 
from the ciliary body into the anterior 
chamber and then into the subconjunctival 
space where a ‘bleb’ of aqueous fluid forms 
(Figs 15 and 16).
Other glaucoma surgical procedures 
(including glaucoma drainage devices) use 
similar principles.
Types of glaucoma
Glaucoma may be broadly classified into 
four groups – primary open-angle glaucoma 
(POAG), angle-closure glaucoma (ACG), 
secondary glaucoma and congenital 
glaucoma.
Primary open-angle glaucoma
POAG, the commonest type of glaucoma, 
typically begins in the fourth to sixth 
decade and affects both sexes equally. It is 
symptomless and is usually picked up on 
routine screening. There is often a family 
history of glaucoma. It is a bilateral, although 
usually asymmetrical disease. The diagnosis 
is made by demonstrating progressive 
functional and structural changes to the 
optic nerve in the absence of a secondary 
cause. The IOP may or may not be elevated. 
In addition, the drainage angle of the eye 
is visualised (gonioscopy) with a mirrored 
contact lens (gonioscopic lens). In an ‘open’ 
angle the trabecular meshwork is visible in 
the mirrored portion of the lens (Fig. 17).
Angle-closure glaucoma
On gonioscopy these patients have a ‘closed’ 
drainage angle – the trabecular meshwork 
is not visible because it is obscured by the 
peripheral iris. This can cause chronically 
elevated IOPs, in which case it presents 
similarly to POAG. A clinically completely 
different picture arises in acute-angle 
closure. 
Acute-angle closure
This occurs in patients with anatomically 
narrow anterior segments. As these patients 
age, so their lenses increase in size. In this 
setting they may develop relative ‘pupil 
block’ when the pupil is in the mid-dilated 
position as occurs in dim lighting or may 
be precipitated by pharmacological pupil 
dilatation or by systemic drugs (Table I).6
Fig. 18 demonstrates how this can occur – 
the pupil comes to rest on the lens, blocking 
the flow of aqueous into the anterior 
chamber. Aqueous then collects behind the 
iris, causing this to bulge forwards and block 
off the trabecular meshwork. The result is a 
dramatic and sudden increase in the IOP 
over minutes to hours causing excruciating 
pain, headache, nausea and vomiting and 
an associated red, angry eye with corneal 
oedema and a diminished visual acuity. This 
is a medical emergency.
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Fig. 13. Medical therapy for glaucoma.
Fig. 14. Scleral flap construction during a  
trabeculectomy.
Fig. 15. The anatomy of a trabeculectomy.
Fig. 16. A trabeculectomy postoperatively.
Fig. 17. Gonioscopic view of the angle of the eye.
Table I. Systemic drugs and angle 
closure6
•   Phenothiazines and their derivatives
•    Tricyclic and non-tricyclic antidepres-
sants
•   Monoamine oxidase inhibitors
•   Topiramate
•   Antihistamines
•   Antiparkinsonian drugs
•   Parasympatholytic agents
•   Sympathomimetic agents
Fig. 18. The dynamics of pupil block in acute- 
angle closure.
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Treating acute angle closure
The first priority is to decrease the 
IOP. This can be achieved with 500 mg 
acetazolamide IVI stat, followed by 500 
mg oral acetazolamide. Analgesics and 
anti-emetics may also be required. The 
patient should then be referred to an 
ophthalmologist who may perform a laser 
peripheral iridotomy. By creating a hole in 
the peripheral iris, aqueous is allowed into 
the anterior chamber, restoring the iris 
anatomy and aqueous outflow channels to 
normal. The definitive treatment may be 
cataract surgery to replace the enlarged lens 
with an intraocular lens, thus preventing 
the situation from occurring again.
Secondary glaucoma
Any process disturbing the functioning of 
the trabecular meshwork will increase the 
IOP and may cause secondary glaucoma. 
Some of the commoner examples of this 
(there are numerous causes) are:
•    uveitic glaucoma – peripheral anterior 
synechiae form between the iris and the 
peripheral cornea ‘closing’ the drainage 
angle
•    rubeotic glaucoma – neovascularisation 
of the iris secondary to retinal ischaemia 
begins in the angle, causing an elevated 
IOP
•    traumatic glaucoma – blunt trauma 
to the eye may tear the iris root and 
damage the trabecular meshwork.
Congenital glaucoma
Some infants have congenitally abnormal 
drainage angles which may be unilateral or 
bilateral. The elevated IOP that this causes 
produces not only an optic neuropathy, 
but also an enlarged eye (buphthalmos) 
because the sclera and cornea are still 
elastic in infants. The cornea may also 
become opacified. Treatment of congenital 
glaucoma is predominantly surgical to 
open the drainage angle and decrease the 
IOP.
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In a nutshell 
•   Glaucoma is an optic neuropathy.
•    The diagnosis of glaucoma is made on the basis of specific structural (cupping of the optic nerve head) and functional (visual field) 
changes. The monitoring of progression within these changes is essential in the follow-up of patients with established glaucoma.
•   Intraocular pressure (IOP) is the most important risk factor for glaucoma, but does not form part of the diagnosis of the disease.
•   Reducing IOP is currently the only way we have to treat glaucoma. 
•   The lowering of IOP may be achieved medically (predominantly with topical therapy), with laser treatment or surgically.
•   The broad categories of glaucoma are:
      •   primary open-angle glaucoma
     •   primary closed-angle glaucoma
     •   secondary glaucoma
     •   congenital glaucoma.
•    Acute-angle closure is a medical emergency requiring immediate IOP lowering with acetazolamide followed by urgent referral to an 
ophthalmologist for laser iridotomy.
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